IMMIX BIOPHARMA INC.

IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale

25 Jan 2022 09:15:00 By Nasdaq GlobeNewswire

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles

19 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

12 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders

06 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

03 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Immix Biopharma, Inc. Announces Closing of Initial Public Offering

20 Dec 2021 15:16:19 By Nasdaq GlobeNewswire

Immix Biopharma, Inc. Announces Pricing of Initial Public Offering

15 Dec 2021 16:59:56 By Nasdaq GlobeNewswire